Naptumomab estafenatox  (Synonyms: ABR-217620; ANYARA)

Naptumomab estafenatox (ABR-217620) is a tumor targeting superantigen (TTS). Naptumomab estafenatox is a fusion protein containing an anti-5T4 antibody and a SEA/E-120 superantige. Naptumomab estafenatox can be used for the research of lung cancer^[1].

Naptumomab estafenatox (0.001-10000 pM; 4 hour) shows cytotoxicity with EC₅₀ values of 20 and 30000 pM for Caki-2 and Raji cells by human staphylococcal enterotoxin A (SEA) reactive T cells^[1].
Naptumomab estafenatox (0.001-10000 pM; 4 hour) shows cytotoxicity with EC₅₀ values of 0.1 and 100000 pM for Caki-2 and Raji cells by SEA/E-120 activated T cells^[1].
Naptumomab estafenatox (1 pM-1 μM; 4 days) dose-dependently induces the proliferation of human lymphocytes^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Naptumomab estafenatox (0.016 mg; i.v., daily injection, for 8 days) shows antitumor effects in SCID mice with Calu-1 tumor^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

676258-98-3

[Naptumomab estafenatox]

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Forsberg G, et al. Naptumomab estafenatox, an engineered antibody-superantigen fusion protein with low toxicity and reduced antigenicity. J Immunother. 2010 Jun;33(5):492-9.  [Content Brief]

  [2]. Elkord E, et al. Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-α versus IFN-α. Oncotarget. 2015 Feb 28;6(6):4428-39.  [Content Brief]